These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 28323042

  • 1. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
    Archer DF, Labrie F, Montesino M, Martel C.
    J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 4. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
    Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É, Members of the VVA Prasterone Group.
    Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
    [Abstract] [Full Text] [Related]

  • 5. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH.
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [Abstract] [Full Text] [Related]

  • 6. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J.
    J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
    [Abstract] [Full Text] [Related]

  • 7. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
    Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi É, Grainger DA, Ayotte N, Cooper TA, Martens M, Waldbaum AS, Labrie C, Côté I, Lavoie L, Martel C, Balser J, VVA Prasterone Group.
    Climacteric; 2015 Jul; 18(4):590-607. PubMed ID: 25511551
    [Abstract] [Full Text] [Related]

  • 8. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
    Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J, VVA Prasterone Group.
    Menopause; 2015 Sep; 22(9):950-63. PubMed ID: 25734980
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
    Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J.
    Gynecol Endocrinol; 2016 Sep; 32(3):240-5. PubMed ID: 26634942
    [Abstract] [Full Text] [Related]

  • 10. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, Members of the VVA Prasterone Research Group.
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [Abstract] [Full Text] [Related]

  • 11. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
    Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M.
    Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
    [Abstract] [Full Text] [Related]

  • 12. Prasterone: A Review in Vulvovaginal Atrophy.
    Heo YA.
    Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
    [Abstract] [Full Text] [Related]

  • 13. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, other participating members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [Abstract] [Full Text] [Related]

  • 14. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
    Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, Gomez JL.
    J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
    [Abstract] [Full Text] [Related]

  • 15. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
    Labrie F, Montesino M, Archer DF, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    Climacteric; 2015 Nov; 18(6):817-25. PubMed ID: 26517756
    [Abstract] [Full Text] [Related]

  • 16. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
    Constantine GD, Simon JA, Pickar JH, Archer DF, Bernick B, Graham S, Mirkin S.
    Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
    [Abstract] [Full Text] [Related]

  • 17. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
    Portman DJ, Goldstein SR, Kagan R.
    Climacteric; 2019 Feb; 22(1):65-72. PubMed ID: 30554531
    [Abstract] [Full Text] [Related]

  • 18. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH.
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [Abstract] [Full Text] [Related]

  • 19. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
    Kroll R, Archer DF, Lin Y, Sniukiene V, Liu JH.
    Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
    Pickar JH, Amadio JM, Hill JM, Bernick BA, Mirkin S.
    Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.